1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow TP53 Y220C Mutation: new trials by email Literature Review of TP53 Y220C Mutation trials Research Report on TP53 Y220C Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet - TP53 Y220C Mutation, Advanced Solid Tumors | Phase 1 | Recruiting | PMV Pharmaceuticals, Inc | 14 | 2026-02-04 | 2026-08-12 |
Metformin (1) · Rosuvastatin Calcium (1) · Tablets (1) · repaglinide (1)
United States (1)